Association between duration of use of pharmacotherapy and smoking cessation

Findings from a national survey

Mohammad Siahpush, Raees A. Shaikh, Molly McCarthy, Asia Sikora Kessler, Melissa K Tibbits, Gopal K. Singh

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: To investigate the association of the duration of use of prescription medications and nicotine replacement therapy (NRT) with smoking cessation using a national sample of the general population in the USA, controlling for nicotine dependence and sociodemographic variables. Setting: USA. Participants: We used data from the 2010-2011 Tobacco Use Supplement to the US Current Population Survey. We limited the analysis to current daily smokers who made a quit attempt in the past year and former smokers who were a daily smoker 1 year prior to the survey (n=8263). Respondents were asked about duration of use of prescription medication (varenicline, bupropion, other) and NRT (nicotine patch, gum/lozenges, nasal spray and inhaler) for smoking cessation. Primary outcome measure: Successful smoking cessation. Individuals who reported to have smoked at least 100 cigarettes in their lifetime but were not smoking at all at the time of the interview and were a daily smoker 1 year prior to the interview were considered to have successfully quit smoking. Results: After adjusting for daily cigarette consumption and sociodemographic covariates, we found evidence for an association between duration of pharmacotherapy use and smoking cessation (p<0.001). Adjusted cessation rates for those who used prescription medication or NRT for 5+ weeks were 28.8% and 27.8%, respectively. Adjusted cessation rates for those who used prescription medication or NRT for less than 5 weeks varied from 6.2% to 14.5%. Adjusted cessation rates for those who used only behavioural counselling and those who attempted to quit smoking unassisted were 16.1% and 16.4%, respectively. Conclusions: Use of pharmacotherapy for at least 5 weeks is associated with increased likelihood of successful smoking cessation. Results suggest that encouraging smokers who intend to quit to use pharmacotherapy and to adhere to treatment duration can help improve chances of successful cessation.

Original languageEnglish (US)
Article numbere006229
JournalBMJ open
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Smoking Cessation
Nicotine
Prescriptions
Drug Therapy
Smoking
Tobacco Products
Interviews
Tobacco Use Cessation Products
Nasal Sprays
Therapeutics
Bupropion
Tobacco Use Disorder
Nebulizers and Vaporizers
Tobacco Use
Gingiva
Population
Counseling
Outcome Assessment (Health Care)
Surveys and Questionnaires

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Association between duration of use of pharmacotherapy and smoking cessation : Findings from a national survey. / Siahpush, Mohammad; Shaikh, Raees A.; McCarthy, Molly; Sikora Kessler, Asia; Tibbits, Melissa K; Singh, Gopal K.

In: BMJ open, Vol. 5, No. 1, e006229, 01.01.2015.

Research output: Contribution to journalArticle

Siahpush, Mohammad ; Shaikh, Raees A. ; McCarthy, Molly ; Sikora Kessler, Asia ; Tibbits, Melissa K ; Singh, Gopal K. / Association between duration of use of pharmacotherapy and smoking cessation : Findings from a national survey. In: BMJ open. 2015 ; Vol. 5, No. 1.
@article{d297f0edf9f64fabb3ef54869c745ac6,
title = "Association between duration of use of pharmacotherapy and smoking cessation: Findings from a national survey",
abstract = "Objective: To investigate the association of the duration of use of prescription medications and nicotine replacement therapy (NRT) with smoking cessation using a national sample of the general population in the USA, controlling for nicotine dependence and sociodemographic variables. Setting: USA. Participants: We used data from the 2010-2011 Tobacco Use Supplement to the US Current Population Survey. We limited the analysis to current daily smokers who made a quit attempt in the past year and former smokers who were a daily smoker 1 year prior to the survey (n=8263). Respondents were asked about duration of use of prescription medication (varenicline, bupropion, other) and NRT (nicotine patch, gum/lozenges, nasal spray and inhaler) for smoking cessation. Primary outcome measure: Successful smoking cessation. Individuals who reported to have smoked at least 100 cigarettes in their lifetime but were not smoking at all at the time of the interview and were a daily smoker 1 year prior to the interview were considered to have successfully quit smoking. Results: After adjusting for daily cigarette consumption and sociodemographic covariates, we found evidence for an association between duration of pharmacotherapy use and smoking cessation (p<0.001). Adjusted cessation rates for those who used prescription medication or NRT for 5+ weeks were 28.8{\%} and 27.8{\%}, respectively. Adjusted cessation rates for those who used prescription medication or NRT for less than 5 weeks varied from 6.2{\%} to 14.5{\%}. Adjusted cessation rates for those who used only behavioural counselling and those who attempted to quit smoking unassisted were 16.1{\%} and 16.4{\%}, respectively. Conclusions: Use of pharmacotherapy for at least 5 weeks is associated with increased likelihood of successful smoking cessation. Results suggest that encouraging smokers who intend to quit to use pharmacotherapy and to adhere to treatment duration can help improve chances of successful cessation.",
author = "Mohammad Siahpush and Shaikh, {Raees A.} and Molly McCarthy and {Sikora Kessler}, Asia and Tibbits, {Melissa K} and Singh, {Gopal K.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1136/bmjopen-2014-006229",
language = "English (US)",
volume = "5",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Association between duration of use of pharmacotherapy and smoking cessation

T2 - Findings from a national survey

AU - Siahpush, Mohammad

AU - Shaikh, Raees A.

AU - McCarthy, Molly

AU - Sikora Kessler, Asia

AU - Tibbits, Melissa K

AU - Singh, Gopal K.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective: To investigate the association of the duration of use of prescription medications and nicotine replacement therapy (NRT) with smoking cessation using a national sample of the general population in the USA, controlling for nicotine dependence and sociodemographic variables. Setting: USA. Participants: We used data from the 2010-2011 Tobacco Use Supplement to the US Current Population Survey. We limited the analysis to current daily smokers who made a quit attempt in the past year and former smokers who were a daily smoker 1 year prior to the survey (n=8263). Respondents were asked about duration of use of prescription medication (varenicline, bupropion, other) and NRT (nicotine patch, gum/lozenges, nasal spray and inhaler) for smoking cessation. Primary outcome measure: Successful smoking cessation. Individuals who reported to have smoked at least 100 cigarettes in their lifetime but were not smoking at all at the time of the interview and were a daily smoker 1 year prior to the interview were considered to have successfully quit smoking. Results: After adjusting for daily cigarette consumption and sociodemographic covariates, we found evidence for an association between duration of pharmacotherapy use and smoking cessation (p<0.001). Adjusted cessation rates for those who used prescription medication or NRT for 5+ weeks were 28.8% and 27.8%, respectively. Adjusted cessation rates for those who used prescription medication or NRT for less than 5 weeks varied from 6.2% to 14.5%. Adjusted cessation rates for those who used only behavioural counselling and those who attempted to quit smoking unassisted were 16.1% and 16.4%, respectively. Conclusions: Use of pharmacotherapy for at least 5 weeks is associated with increased likelihood of successful smoking cessation. Results suggest that encouraging smokers who intend to quit to use pharmacotherapy and to adhere to treatment duration can help improve chances of successful cessation.

AB - Objective: To investigate the association of the duration of use of prescription medications and nicotine replacement therapy (NRT) with smoking cessation using a national sample of the general population in the USA, controlling for nicotine dependence and sociodemographic variables. Setting: USA. Participants: We used data from the 2010-2011 Tobacco Use Supplement to the US Current Population Survey. We limited the analysis to current daily smokers who made a quit attempt in the past year and former smokers who were a daily smoker 1 year prior to the survey (n=8263). Respondents were asked about duration of use of prescription medication (varenicline, bupropion, other) and NRT (nicotine patch, gum/lozenges, nasal spray and inhaler) for smoking cessation. Primary outcome measure: Successful smoking cessation. Individuals who reported to have smoked at least 100 cigarettes in their lifetime but were not smoking at all at the time of the interview and were a daily smoker 1 year prior to the interview were considered to have successfully quit smoking. Results: After adjusting for daily cigarette consumption and sociodemographic covariates, we found evidence for an association between duration of pharmacotherapy use and smoking cessation (p<0.001). Adjusted cessation rates for those who used prescription medication or NRT for 5+ weeks were 28.8% and 27.8%, respectively. Adjusted cessation rates for those who used prescription medication or NRT for less than 5 weeks varied from 6.2% to 14.5%. Adjusted cessation rates for those who used only behavioural counselling and those who attempted to quit smoking unassisted were 16.1% and 16.4%, respectively. Conclusions: Use of pharmacotherapy for at least 5 weeks is associated with increased likelihood of successful smoking cessation. Results suggest that encouraging smokers who intend to quit to use pharmacotherapy and to adhere to treatment duration can help improve chances of successful cessation.

UR - http://www.scopus.com/inward/record.url?scp=84921929485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921929485&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2014-006229

DO - 10.1136/bmjopen-2014-006229

M3 - Article

VL - 5

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 1

M1 - e006229

ER -